研究项目库 / NCT07849712

Benmelstobart Combined With Anlotinib用于非小细胞肺癌的不适用研究

这是一项关于非小细胞肺癌的不适用研究,登记的药物或干预包括Benmelstobart Combined With Anlotinib,当前状态为尚未开始招募。登记地点显示中国杭州有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

一分钟看懂

这是一项关于非小细胞肺癌的不适用研究,登记的药物或干预包括Benmelstobart Combined With Anlotinib,当前状态为尚未开始招募。登记地点显示中国杭州有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。

药物或干预

Benmelstobart Combined With Anlotinib · 不适用

登记条件中文摘要

年龄范围:75天及以上

登记的基本范围为不限性别,年龄75天及以上;以下仅摘录1项专业入选条件,需结合英文原文并由研究团队确认。

登记记录列出1项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。

中国哪些地方有记录

以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。

  • Zhejiang Cancer Hospital · 杭州

入选条件原文摘录

以下为摘录,请打开原始登记查看完整入排标准。

  • Voluntary signed written Informed Consent Form (ICF). Age $\\ge 75$ years, male or female. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Expected survival time $\\ge 3$ months. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). Unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC that cannot receive radical concurrent/sequential chemoradiotherapy (according to the AJCC/UICC 8th TNM staging). No EGFR sensitive mutations or ALK gene translocations. (Non-squamous NSCLC patients must provide prior tissue test reports; squamous NSCLC patients with unknown status do not require testing and are regarded as negative). Intolerant to or refusing chemotherapy/radiotherapy. At least one measurable target lesion per RECIST v1.1 that can be accurately measured repeatedly. Brain metastases are permitted. Adequate organ function (without blood components or growth factors within 7 days prior to treatment):Hematology: Absolute Neutrophil Count (ANC) $\\ge 1.5 \\times 10\^9/\\text{L}$; Platelets $\\ge 100 \\times 10\^9/\\text{L}$; Hemoglobin $\\ge 90\\text{ g/L}$. Renal: Calculated Creatinine Clearance (CrCl) $\\ge 50\\text{ mL/min}$ (Cockcroft-Gault formula); Urine protein $\\le 1+$ or 24-hour urine protein $\< 1.0\\text{ g}$. Hepatic: Total Bilirubin (TBil) $\\le 1.5 \\times \\text{ULN}$; AST and ALT $\\le 2.5 \\times \\text{ULN}$ ($\\le 5 \\times \\text{ULN}$ for patients with liver metastases); Serum Albumin $\\ge 28\\text{ g/L}$. Coagulation: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) $\\le 1.5 \\times \\text{ULN}$. Cardiac: Left Ventricular Ejection Fraction (LVEF) $\\ge 50\\%$.

联系前需要确认

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

查看登记信息

登记号:NCT07849712;登记信息更新于 2026-09-30;本站同步于 2026-10-08。

查看原始登记记录